What Is Milo Biotechnology?

Milo Biotechnology is company developing a therapy that increases muscle strength or decrease the rate of muscle atrophy for the treatment of muscular disorders.

The company’s technology, a gene therapy-based up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital (Ohio, U.S.A.).

In 2014 the therapy completed a Phase I/II clinical study in Becker Muscular Dystrophy establishing initial safety and efficacy.

Recent News

20Oct

Milo Biotechnology’s Follistatin Gene Therapy Increases Function in Becker Muscular Dystrophy Patients

0 Comments
Data published today in the journal Molecular Therapy demonstrates initial clinical proof of principle of a gene therapy to increase... Read More →
07Nov

Preliminary Findings in Milo Follistatin Gene Transfer Study Promising

0 Comments
Preliminary results from a trial to test the safety of injecting follistatin genes into the thigh muscles of adults with... Read More →
Back to Top